On August 13, 2019, Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE) announced that it closed its previously announced public offering of units (the “Units”) raising aggregate gross proceeds of $8,050,000 (the “Offering”). Each Unit was comprised of one common share and one-half of one common share purchase warrant.
Antibe was represented by WeirFoulds, with a team consisting of Rob Eberschlag, David Knight, Ryan Morris, Dan Tessaro and Irina Lustig.
Antibe develops safer medicines for pain and inflammation. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine.
WeirFoulds is pleased to have assisted Antibe in this public offering.
To learn more about our Securities Practice Group or to contact one of our securities lawyers, visit our securities practice group overview page.
